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Background: MicroRNAs (miRNAs) are a family of short, non-coding RNAs modulating expression of human protein
coding genes (miRNA target genes). Their dysfunction is associated with many human diseases, including
neurodevelopmental disorders. It has been recently shown that genomic copy number variations (CNVs) can cause
aberrant expression of integral miRNAs and their target genes, and contribute to intellectual disability (ID).
Results: To better understand the CNV-miRNA relationship in ID, we investigated the prevalence and function of
miRNAs and miRNA target genes in five groups of CNVs. Three groups of CNVs were from 213 probands with ID
(24 de novo CNVs, 46 familial and 216 common CNVs), one group of CNVs was from a cohort of 32 cognitively
normal subjects (67 CNVs) and one group of CNVs represented 40 ID related syndromic regions listed in DECIPHER
(30 CNVs) which served as positive controls for CNVs causing or predisposing to ID. Our results show that 1). The
number of miRNAs is significantly higher in de novo or DECIPHER CNVs than in familial or common CNV subgroups
(P < 0.01). 2). miRNAs with brain related functions are more prevalent in de novo CNV groups compared to common
CNV groups. 3). More miRNA target genes are found in de novo, familial and DECIPHER CNVs than in the common
CNV subgroup (P < 0.05). 4). The MAPK signaling cascade is found to be enriched among the miRNA target genes
from de novo and DECIPHER CNV subgroups.
Conclusions: Our findings reveal an increase in miRNA and miRNA target gene content in de novo versus common
CNVs in subjects with ID. Their expression profile and participation in pathways support a possible role of miRNA
copy number change in cognition and/or CNV-mediated developmental delay. Systematic analysis of expression/
function of miRNAs in addition to coding genes integral to CNVs could uncover new causes of ID.
Keywords: Micro RNA (miRNA), Copy number variants (CNVs), Copy number variant regions (CNVRs), Intellectual
disabilities (ID), Functional pathwaysBackground
MicroRNAs (miRNAs) are an abundant class of short,
non-coding, endogenous RNAs that regulate gene expres-
sion at the post-transcriptional level [1,2]. The mature
miRNA is a ~20-23 nucleotides long single stranded se-
quence, which derives from primary transcript miRNA
(pri-miRNAs) [3]. One miRNA can bind to hundreds of* Correspondence: eseparovic@cw.bc.ca
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reproduction in any medium, provided the ortarget genes at the 3’-UTR of mRNAs (miRNA target
genes), and a single miRNA target gene can be targeted by
multiple miRNAs [4,5]. Based on bioinformatic predic-
tions, up to 90% of human genes are believed to be regu-
lated by miRNA [5]. MiRNAs have primarily been
demonstrated to mediate translational repression or target
gene degradation and silencing. Recently, it has been
shown that they can also upregulate gene expression by
targeting gene regulatory sequences [6].
Genetic polymorphisms in miRNA or their targets can
add to the complexity of miRNA regulation and func-
tion. Single nucleotide polymorphisms (SNPs) in miRNAd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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miRNA-mediated gene regulation and alter the expres-
sion of target genes [7]. A low SNP density at miRNA
genes exists compared to the reference human genome,
suggesting a negative selection for miRNA with SNPs
[8-10]. CNVs, as a major class of genomic variations, also
have an effect on miRNA, as demonstrated by under-
representation of miRNA in highly polymorphic CNVs
compared to the reference genome [10]. In contrast, the
number of miRNA target genes in polymorphic CNVs is
higher than in non-CNV regions, suggesting that genes in-
tegral to polymorphic CNVs are more likely to be regu-
lated by miRNAs, in order to counteract their expression
changes due to copy number variability of the region in
which they reside [9]. Multiple cancer studies show that
miRNAs integral to CNVs demonstrate gain or loss at the
genomic level, and are associated with expression changes
for ~10% -20% miRNAs [11,12].
In addition to cancer, miRNAs are involved in other hu-
man diseases, for example, cardiovascular diseases and
neurological/neurodevelopmental disorders [13,14]. Evi-
dence for the role of miRNA in these diseases is based on
identifying mutations or differential expression of specific
miRNAs and/or their global expression [15-17], and the ef-
fect of genomic copy number change on miRNA function
is largely unknown. In rare instances association of CNVs
with miRNA expression was studied in subject with cogni-
tive delay. For example in Down syndrome an extra copy
of chromosome 21 was associated with upregulation of
several miRNAs from this chromosome, while their targets
are downregulated [18]. In addition, a deletion of 1p21.3
containing a miRNA MIR137 has recently been reported
by Willemsen et al. [19], and resulted in downregulation of
the miRNA, and upregulation of three targets in subjects
with ID and congenital abnormalities. Considering the role
of MIR137 and its targets in brain function (synapse mat-
uration, morphogenesis of young neurons, and axon
growth), their dysfunction is considered causative of
the patients’ phenotype [19]. Finally, microdeletion of a
miRNA cluster MIR17HG on chromosome 13 is associ-
ated with Feingold syndrome which includes microceph-
aly, skeletal abnormalities and variable levels of ID [20].
The role of this miRNA in the human phenotype is further
supported by a mouse knock-out model [20].
Although the above examples demonstrate the relevance
of copy number change on miRNA function and its role in
human disease, these studies are focusing on one type of
CNV exclusively; for example, on common CNVs from
normal populations [8-10], lump of CNVs from single dis-
ease cohorts such as cancer [11,12] or autism [21], or a few
individual pathogenic CNVs associated with neuro-
developmental disorders [19,20]. Considering that ~ 70% of
miRNAs are expressed in brain [22], and function in
neurodevelopment, neurotransmission, synaptic plasticity,neurite outgrowth and dysregulation [18,23], we aimed to
characterize and understand the total presence and
functions of miRNAs in CNVs detected in idiopathic ID
in comparison to neurotypical controls. Five different
CNV subgroups were studied for their miRNA and
miRNA target gene contents: (i) de novo, (ii) familial,
(iii) common CNVs detected in subjects with idiopathic
ID, (iv) common CNVs in cognitively normal subjects,
and (v) CNVs associated with syndromic ID selected from
DECIPHER (Database of Chromosomal Imbalance and
Phenotype in Humans using Ensembl Resources) database
(http://decipher.sanger.ac.uk/). CNVs from DECIPHER
were considered as positive controls. Our study is unique
in serving as the first report comparing the miRNA con-
tent and function in different CNV subgroups from ID
subjects and cognitively typical controls.Results
CNV detection and sub-classification
Initially, we identified 24 de novo, 46 familial and 216
common CNVs from 213 cases with idiopathic ID, 67
common CNVs from 32 cognitively normal subjects, and
30 CNVs collected from 40 ID-related syndromic regions
in DECIPHER database representing CNVs known to
cause or predispose to developmental delay. All the CNVs
were identified experimentally except the CNVs from DE-
CIPHER which were retrieved from the DECIPHER data-
base. Overlapping CNVs from the same subgroups were
merged into CNVRs (CNV Regions). The final set in-
cluded 22 de novo, 46 familial, 30 DECIPHER CNVRs,
and respectively 210 and 61 common CNVRs from cases
versus controls (Table 1).The genomic coverage (Build 36
hg18) for all CNVRs and the miRNAs present in each
CNVR are provided in Additional file 1: Table S1-S5.Characteristics of miRNA in different CNV subgroups
Number of miRNAs in different CNV groups
The number and loci of miRNAs in different CNV sub-
groups were obtained using Galaxy (https://main.g2.bx.psu.
edu/) and miRBase (http://www.mirbase.org/). To avoid
bias caused by varying CNV size, the number of miRNA in
each CNV region was weighted by the size of the CNV, and
expressed as miRNA/Mb. The weighted median number
of miRNAs/Mb in each CNV subgroup is shown in
Table 1 and was compared among different pairs of
CNV subgroups using the Wilcoxon rank-sum test. We
found the median number of miRNAs/Mb is signifi-
cantly higher in de novo and DECIPHER CNVs than fa-
milial or common CNVs from cases, and common
CNVs from controls (P < 0.01) (Table 1 and Figure 1).
However, the average miRNA/Mb between the common
and pathogenic subgroups is comparable which is likely
due to the presence of few very small common CNVs with















Total No. (#) Average miRNA/Mb #/CNVR Weighted median No.
De novo 24 22 70.5 3.21 84 1.20 3.8 0.6a
Familial 46 46 29.5 3.34 14 0.47 0.3 0b
Common from cases 216 210 105.2 0.64 67 0.64 0.3 0b
Common from control cohort 67 61 34.1 0.56 30 0.88 0.5 0b
Pathogenic from DECIPHER 35 30 100.1 0.50 90 0.90 3.0 0.8a
a,b:Significant difference was found between data a and b (P < 0.05) (a Wilcoxon signed-rank test).
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common CNV at 16p13 (16,322,499-16,682,499).
Genomic coverage of miRNAs in different CNV groups
The genomic coverage of miRNA and protein coding
genes (expressed as their number per CNV group per
their total number in the whole genome) tended to be
higher for de novo and DECIPHER CNVs, in compari-
son to the coverage of miRNAs and protein coding
genes of randomly sampled sections from the reference
genome of the same size as each of the CNV subgroups.
This increase in comparison to the reference genome was
the highest for miRNAs in de novo CNVs, but was not sig-
nificant (p > 0.05, Wilcoxon signed-rank test) (Figure 2).
The de novo and DECIPHER CNV coverage of protein
coding genes was also slightly higher than expected by
chance but not significant. In contrast, the protein coding
genes covered a significantly smaller fraction of the com-
mon CNVs than expected by chance, i.e. when reference
genome of the same size as CNVs was used (P < 0.01)
(Figure 2B), in keeping with their suspected benign nature.
For the familial CNVs, the observed-to-expected miRNA













































Figure 1 Comparison of weighted median number of miRNAs/Mb
in different CNV subgroups.Functional characteristics of miRNA from different CNV
groups
Expression of miRNAs from CNVs
The expression profiles of miRNAs in different CNV
subgroups were obtained using two web-tools, the
mimiRNA database (http://mimirna.centenary.org.au/
mep/formulaire.html) [24] and microRNA.org-Targets
(http://www.microrna.org/microrna/home.do) [25]. Both
web-tools identified a small number of miRNAs (20 ~ 30%
of miRNAs in de novo or familial CNV groups, and ~10%
of miRNAs in common CNV groups) with published ex-
pression profiles. Although the low number of miRNA
with expression/function data does not allow definitive
conclusions, we note that the miRNAs expressed in brain
related tissues and/or having experimental evidence of in-
volvement in nervous system dysfunction (based on man-
ual search of PubMed) seem to be more prevalent in the
de novo, familial and DECIPHER CNV group (~50% of all
de novo, familial and DECIPHER CNV miRNAs with ex-
pression data) than in the common CNVs tested (0-25% of
all common CNV miRNAs with expression data) (Table 2).
A list of miRNAs with available expression data and brain
or nervous system related function is shown in Table 3. In
comparison to the common CNVs from patients, the two
fold increase in the number of brain function related
miRNA in familial CNV group suggests that some genes
in familial CNVs could contribute to the disease process.
There were no brain function-related miRNAs in common
CNVs from cognitively typical controls (Table 2).
Functional and pathways enrichment analysis of miRNA
targets
Using the web-tool WebGestalt, we searched for pathway
enrichment of miRNA target genes from different CNV
subgroups compared to the reference genome. We found
that approximately 8-11% of genes from de novo CNVs,
DECIPHER CNVs or familial CNVs were targeted by
miRNAs in comparison to 0-1% of genes from common
CNV subgroups (P < 0.01; two-sided Fisher’s exact test)
(Table 4). KEGG pathway enrichment analysis was
performed using WebGestalt for identification of pathways
Protein coding gene coverage
CNVs in our datasets
Reference genome with similar length of CNVs
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Figure 2 Genomic coverage of miRNA (A) and protein coding genes (B) in different CNV subgroups. The fraction was defined as observed
number of miRNA (or protein coding genes) in each CNV group divided by the total miRNAs (or total number of protein coding genes) in
human genome. The miRNA or gene fraction in CNVs was compared to the miRNA or gene fraction in the reference genome which was
generated by extracting random DNA fragments with similar length to the respective CNVs 1000 times from human genome. * Indicates p < 0.05
(a Wilcoxon signed-rank test). 1: De novo CNVs; 2: DECIPHER CNVs; 3: Familial CNVs; 4: Common CNVs from controls; 5: Common CNVs from cases.
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groups. The top 10 pathways are listed in Table 4 and
contained nervous system-related pathways (Axon guid-
ance and Neurotrophin signaling, respectively) for only
de novo and DECIPHER CNVs (Table 4). We found that
targets from both de novo and DECIPHER CNVs par-
ticipate in MAPK signaling pathways more thanTable 2 Expression/Function of miRNAs in different CNV
groups
CNV category No. of
miRNA






De novo 84 18 10 (55%)












90 24 11 (46%)
Notes: *indicates data collected from websites: http://www.microrna.org/
microrna/ and mimiRNa (http://mimirna.centenary.org.au/mep/mir.htm).
**indicate manual PubMed search for each miRNA.expected by chance. Ubiquitin-mediated proteolysis was
the only pathway found to be enriched for miRNA tar-
get genes in the familial CNV subgroup. There was no
apparent pathway enrichment for the miRNA target
genes from our common CNV subgroup. The miRNAs
targeting the genes from the top 10 pathways for each
of our CNV subgroups are also listed in Table 4.
Discussion
MiRNA-mediated gene regulation is complex and gen-
omic variations, such as CNVs and SNPs, which can
modulate miRNA expression, add to this complexity.
The miRNA-CNV relationship has been rarely studied
and predominantly involved polymorphic CNVs found
in control cohorts [9,10].
Our study is novel in its comparison of miRNA content
in different classes of CNVs detected in a cohort of sub-
jects with ID relative to cognitively typical subjects. We
found a significant increase in the number of miRNAs in
de novo and DECIPHER CNVs versus common CNVs
(weighted median 0.6 and 0.8 versus 0.0, P < 0.05). In
addition, the miRNAs in de novo CNVs were more likely
to have expression in brain-related tissues or cell lines
compared to the miRNAs from common CNV groups.
Our collective findings suggest that miRNAs from de
novo and putatively pathogenic CNVs could contribute
Table 3 MiRNAs with expression and/or function related to brain or nervous system




Expression* Functional relevance** Reference
1 1103258 1103279 hsa-
miR-
200a/b









1 1104435 1104456 hsa-
miR-429
de novo cancer-related non-brain cancer related; neuroprotective
effect in in vitro ischemia
PMID: 21684154;
PMID: 20576953
5 87962684 87962705 hsa-
miR-9
de novo brain, astrocytoma,
neuroblastoma
Upregulation in HD (Huntington’s disease);
involved in spinal motor neuron disease;




5 179442361 179442382 hsa-
miR-340
de novo neuroblastoma cancer-related including neuroblastoma PMID: 22797059
7 99691233 99691253 hsa-
miR-25
de novo neuroblastoma neural stem cells differentiation PMID: 21386132
7 99691438 99691460 hsa-
miR-93
de novo cervix-Hela neural stem cells differentiation PMID: 21386132
7 99691625 99691646 hsa-
miR-
106b
de novo Neurobl-SHSY5Y_IFN, AML-
THP1, kidney-embryo-HEK2




19 4770712 4770734 hsa-
miR-7
de novo neuroblastoma Repression of alpha-synuclein accumaulation
in Parkinson’s disease; brain cancers
PMID: 20106983;
PMID: 21912681
20 61151558 61151579 hsa-
miR-1
de novo heart, thyroid, Ewing-
sarcoma




20 61809866 61809887 hsa-
miR-124
de novo hsa-hippocamp-adult, hsa-
celebellum-adult
neuronal differentiation and
incorporation of neural-specific exons;
increased in fmr1/fxr2 knock-out mice
PMID: 17679093
PMID:21957233





non-brain cancer related PMID: 22970209






rectal cancer-specific PMID: 22850566






cancer-related including neuroblastoma PMID: 21498633
Notes: *indicates data collected from websites: http://www.microrna.org/microrna/ and mimiRNa (http://mimirna.centenary.org.au/mep/mir.htm).
**indicate manual PubMed search for each miRNA.
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gral to CNVs.
Similar to the increase in the number of miRNAs in
de novo and DECIPHER CNVs, the number of miRNA
target genes integral to these CNV types was also higher
in comparison to familial or common CNVs. Lower
numbers of miRNAs and miRNA target genes in com-
mon CNVs compared to the de novo or pathogenic
CNVs suggests that they participate in processes that
can tolerate functional variation. Previous studies have
shown that targets for miRNAs from polymorphic
CNVs tend to participate in environment-orientated
processes including stimulus responses and immune re-
sponses, while the targets from non-CNV regions of the
genome are enriched for fundamental biological pro-
cesses such as maintenance of chromatin, chromosome
segregation and nucleic acid processes [26]. In ourstudy, genes from common CNVs that are targets for
miRNAs do not show enrichment in any pathway while
those from familial CNVs show enrichment in ubiquitin
mediated proteolysis. In contrast, brain function related
pathways such as axon guidance, Huntington’s disease,
neutrophin signaling pathway, are found to be among
the top 10 pathways enriched for targets from de novo
and pathogenic CNVs. Targets from these two CNV
groups also showed enrichment in the MAPK (mitogen-
activated protein kinase) signaling pathway. The MAPK
signaling cascade is involved in a wide variety of cellular
processes and has been recently reported to be involved
in ID pathogenesis [27-29]. Seven genes from de novo
and DECIPHER CNVs which are targets for miRNAs
were found to be involved in the MAPK pathway
(MAPK9, MAPT, MEF2C, MKNK2, PAK2, RPS6KA1,
and TAOK2). Three of them are known to be related to












miRNA targeting the genes in CNVs in enrichment analysis
De novo from
ID





















































266 3 (1.1%)b N/A MIR-526B
Notes: Significant difference was found between data a and data b (P < 0.05) (a two sided Fisher’s exact test). N/A: not available.
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number changes of these targets could affect their
regulation by miRNA. Target genes for CNV miRNAs
detected in subjects with autism were also found to be
enriched in MAPK pathway [21].
For familial CNVs we noted that although the number
of miRNAs is much lower than in de novo or DECIPHERpathogenic CNV groups, and not different than in com-
mon CNVs, the number of miRNA target genes was sig-
nificantly higher than in common CNVs. This might
suggest potential phenotypic impact of these familial
CNVs. In our cohort we had two familial CNVs, predis-
posing to ID: 16p11.2 and 1q21.1. These CNVs are well-
known for their heterogeneous phenotypes and familial or
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miRNA of unknown role (miR-5087), while the 16p11.2
paternal duplication covers 2 miRNAs: miR-3680-3p and
miR-3680-5p and the de novo 16p11.2 deletion has no
miRNA content (Additional file 1: Table S2). Conse-
quences of the variability in copy number and function of
miRNA integral to these CNVs is yet unknown. Under-
standing the role of miRNAs and miRNA targets in famil-
ial CNVs is of interest since this type of CNV represents a
significant and clinically relevant interpretational challenge
that could be guided by their miRNA features.
The ultimate proof that miRNAs influence the patho-
genicity of genomic changes will come from an empirical
confirmation of their copy number and expression change,
and influence on the expression of their targets. The limi-
tation of our own and other studies is due to their depend-
ence on accurate prediction of miRNA targets and the fact
that miRNA numbers increase dramatically between dif-
ferent versions of miRBase database. Therefore, compari-
son between different studies in terms of miRNA content
in CNVs is challenging. Furthermore, some miRNAs may
still represent false positive discoveries [10]. Unfortunately,
we do not have miRNA expression data from our CNVs
as RNA was not available. However, a recent study by
Garcia-Orti et al. [34], demonstrated 10% of 259 studied
miRNAs from regions of gain and loss detected in AML
had significant change in expression concordant with the
type of copy number change.
A more recently published study highlighted the sig-
nificance of specific CNV-miRNAs and their targets in
autism [21]. It assessed the content and function of 378
autism-associated CNVs, and detected 71 miRNAs. Five
miRNAS were previously reported in ASD and 3 were
known to have neuronal function. In our study, among
the 84 miRNAs in the de novo CNVs, 3 were found
to be associated with neurodegenerative disorders
(miRNA-7, miRNA-9, miRNA-106b) [35-37] and 1 with
ID (miRNA-9) [37].
Our analysis of miRNAs and miRNA targets related to
CNVs is a first attempt to evaluate their role in a patient
cohort manifesting idiopathic intellectual disabilities. Add-
itional studies of cohorts of subjects with ID would benefit
further evaluation of the apparent increase in miRNA con-
tent in de novo CNVs demonstrated in this study. In clin-
ical practice, the interpretation of miRNAs that occur in
patient CNVs is frequently challenging, particularly if they
are the only genes that are included in the CNV. With glo-
bal investigations of miRNAs in subjects with ID, followed
by their expression analysis, our understanding of the role
of miRNA in ID pathogenesis will be further improved.
Conclusions
Our findings support a possible role of miRNA copy
number change in cognition and/or CNV-mediateddevelopmental delay based on increased number of
miRNA and miRNA target genes in de novo versus com-
mon CNVs in subjects with ID as well as their expres-
sion profile and participation in pathways. Systematic
analysis of expression/function of miRNAs in addition




213 subjects with idiopathic ID were recruited for array
CGH analysis by clinical geneticists across Canada.
Selected individual or groups of cases were reported
previously [38-42]. A cohort of 32 cognitively normal
subjects had array testing as internal control samples.
All of the subjects were tested by either Agilent 105 K
Oligo array (227 subjects) or NimbleGen array (18 sub-
jects). Forty syndromic genomic regions were selected
from the DECIPHER database (http://decipher.sanger.ac.
uk/) [43] and represented patients with neurode-
velopmental delay associated with CNV findings of
established potential for pathogenicity. The use of the
DNA from these patients in our cohort was approved by
the Committee for Ethical Review of Research involving
Human Subjects, University of British Columbia. All sub-
jects gave written informed consent for participation in
the study and anonymized data were used for CNV/
miRNA analysis.
Array CGH
Genomic DNA was extracted from peripheral blood using
PUREGENE DNA Isolation Kits (Gentra, Minneapolis,
MN). A pool of normal male or female control DNAs
(Promega, Madison, WI) was used as reference DNA
matching the sex of the proband samples.
Agilent 105 K array analysis was performed according
to the protocol provided by the company (version 4.0,
June 2006, Agilent Technologies, CA, USA) [44]. Fea-
ture Extraction software (version 8.1.1.1, Agilent Technolo-
gies) rendered image analysis using the manufacturer’s
recommended settings (CGH_v4_95) and human genome
assembly hg18. The minimum absolute average of log2 ra-
tio was 0.25.
Higher-resolution 385 K oligonucleotide genome array
CGH was performed courtesy of NimbleGen. Array log2
ratio > ±0.2 was used for a segmentation (region).
For both the Agilent and Nimblegen array platforms, ≥3
consecutive probes were required for a significant CNV
call. CNVs that overlapped in genomic coverage were con-
sidered to represent the same CNV loci.
Types of CNVs
All detected CNVs were grouped into 3 subgroups (de
novo, familial and common CNVs) based on the criteria
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overlapping with variants reported in at least two stud-
ies in the Database of Genomic Variants (DGV) (http://
projects.tcag.ca/variation/) or in our internal controls
were considered common CNVs; CNVs that overlapped
partially (<50%) or did not overlap with CNVs reported
in the DGV or our internal controls were called rare
CNVs including de novo (not detected in proband’s par-
ents) and familial CNVs (inherited from either of par-
ents). All unique CNVs (de novo and familial) were
confirmed by an independent secondary method (such
as FISH method) and only single copy gains or losses
were identified.Bioinformatics analysis
The complete list of miRNAs in the whole genome was
downloaded from miRBase v19 (http://www.mirbase.
org/) [46], containing >2000 mature miRNAs in human.
The miRNAs in different CNV subgroups were obtained
by using intersecting tool in Galaxy (https://main.g2.bx.
psu.edu/) [47].
The expression profiles of miRNAs were obtained by
using mimiRNA database (http://mimirna.centenary.org.
au/mep/formulaire.html) [24] and microRNA.org - Targets
and Expression (http://www.microrna.org/microrna/home.
do) [25]. Both web-tools provide experimentally derived
miRNA expression data after inputting a specific
miRNA name.
The genomic locations of 19,905 human protein cod-
ing genes (PCG) were extracted from the MISO database
(http://genes.mit.edu/burgelab/miso/index.html). Gene
content of different CNV subgroups was obtained by
considering genes within or covering CNV regions.
WebGestalt2 (WEB-based GEne SeT AnaLysis Toolkit
V2) (http://bioinfo.vanderbilt.edu/webgestalt/) is a publicly
available web-tool for functional enrichment analysis of
gene sets using a web-based integrated data mining system
[48]. Using hypergeometric test, the top 10 groups of pro-
tein coding genes from each CNV subgroup that are targets
for miRNA were generated by this tool and ranked by adjP
(p value adjusted by multiple test adjustment). Among
these miRNA target genes, only those with adjP < 0.05, i.e.
distributed in CNVs more often than expected when
compared to reference genome, were selected for
Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway enrichment analysis. Similarly, the top ten
KEGG pathways enriched for miRNA target gene were
generated by the same tool for each CNV subgroup.
Only the top ten enriched pathways with adjP < 0.05
were selected and compared between different CNV
subgroups. The WebGestalt2 tool was also used to
identify miRNAs that target the target genes for each
CNV group.Statistical analysis
All statistical analyses were performed in R 2.12
MiRNA and protein coding gene (PCG) coverage relative to
random distribution: for each CNV/CNVR subgroup we
generated a set of random CNV/CNVRs with similar
length distribution and total genome coverage. The num-
ber of miRNA regions and PCG regions affected by these
random CNV/CNVRs was assessed. This operation was
repeated 1000 times for each of the 5 CNV subgroups,
generating a series of values that served as a measurement
of the miRNA and PCG coverage of CNV/CNVRs under
a random distribution. We performed a two-tailed test to
compute the p value of the actual miRNA and PCG cover-
age of the 5 CNV/CNVR subsets. The p values were cal-
culated as the number of values falling above (or below)
the observed miRNA and gene coverage of the actual
CNVRs datasets.
Comparison of miRNA and PCG content: we computed
the number of miRNA and PCG in the individual CNVs
relative to their size i.e. the number of miRNA and PCG
per Mb. We compared the subgroups to each other using
a Wilcoxon signed-rank test to assess whether a group has
a significantly different miRNA and PCG density.
In order to determine the significance of the number
miRNA related to brain function, we compared the frac-
tion of brain-function related miRNA in the pool of avail-
able CNV-miRNA between each pair of CNV subgroups.
The statistical p value was computed using a two-sided
Fisher’s exact test. Similarly, we performed two-sided
Fisher’s exact tests to compare the fraction of genes
targeted by miRNA in the different CNV subgroups using
the total number of genes encompassed by the CNVs.
Additional file
Additional file 1: Genomic coordinates of CNV/CNVRs and miRNAs
used in this study.
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